How has the UK compared to its European peers in terms of supporting growth and innovation in the pharmaceutical sector? And with a renegotiation of the PPRS pricing deal imminent, Leela
The UK pharmaceutical industry is mounting a legal challenge to NICE and NHS England in court – but the credibility of one of its key witnesses has been called into question.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh